Nimesulide drug was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available in more than 50 countries worldwide with different trademarks.
Nimesulide is a relatively COX-2 selective, with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, Osteoarthritis and primary dysmenorrhoea.
Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.
It is available in the market in various like tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).
Nimesulide trademarks such as Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan.
It has superior gastrointestinal safety as compared to other NSAIDs.
Nimesuilde is the best prescribed pain killer drug for the treatment of acute pain, Primary dysmennorhea and also to treat degenerative joint disease.
Unlike, other NSAIDs, the chemical structure of nimesulide does not contain a carboxylic group but a sulfonanilide moiety as the acidic group.